1.Date of occurrence of the event:2022/05/03
2.Company name:OBI Pharma Inc.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office
4.Reciprocal shareholding ratios:Not applicable
5.Cause of occurrence:OBI Pharma Inc. was informed by the patent office that patent for OBI-999 ”Conjugated Biological Molecules, Pharmaceutical Compositions and Methods“ has been granted by Taiwan Intellectual Property Office under the patent number 106140308.
OBI-999 is an Antibody Drug Conjugate (ADC) for cancer treatment that is based on Globo H to target cancer cells. ADC releases a small molecule payload through the specificity of the antibody and directly deploys cytotoxic molecule at the targeted cancer cells. Antibody that is linked with a payload binds to the targets on tumor cells followed by entering into cells via internalization. The small molecule payload will then be released through enzymatic cleavage to prevent tumor cell differentiation, to achieve the goal of anti-tumor activity. OBI-999 has been granted by TFDA to proceed to Phase II human clinical study and is now open for enrollment in health facilities both in Taiwan and the United States. Please refer to the Company’s material information announcement on October 21,2021. Clinical trial information:
Taiwan
https://www1.cde.org.tw/ct_taiwan/search_case2.php?caseno_ind%5B1%5D=8793
The United States
https://www.clinicaltrials.gov/ct2/show/NCT04084366
6.Countermeasures:None
7.Any other matters that need to be specified:New drug development is a long process associated with high costs. It is not a guaranteed success, which may increase the risk of investment. Investors shall make prudent judgments and investment decisions.